A One-Year Phase 3, Open-Label Study to Evaluate the Safety and Tolerability of TAK-491 in Subjects With Essential Hypertension.

Trial Profile

A One-Year Phase 3, Open-Label Study to Evaluate the Safety and Tolerability of TAK-491 in Subjects With Essential Hypertension.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jan 2016

At a glance

  • Drugs Azilsartan medoxomil (Primary) ; Chlortalidone; Hydrochlorothiazide
  • Indications Essential hypertension
  • Focus Adverse reactions; Registrational
  • Sponsors Takeda; Takeda Global Research and Development Center
  • Most Recent Events

    • 19 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Apr 2010 Actual patient number (669) added as reported by ClinicalTrials.gov.
    • 19 Jun 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top